979P Initial results from the phase II randomized trial comparing TACE with irinotecan and mitomycin C to doxorubicin in intermediate stage HCC (IRITACE trial).
Saved in:
| Title: | 979P Initial results from the phase II randomized trial comparing TACE with irinotecan and mitomycin C to doxorubicin in intermediate stage HCC (IRITACE trial). |
|---|---|
| Authors: | Waidmann, O.1 (AUTHOR), Gruber-Rouh, T.2 (AUTHOR), Koch, C.3 (AUTHOR), Götze, T.O.4 (AUTHOR), Schultheiss, M.5 (AUTHOR), Herrmann, E.6 (AUTHOR), Steup, C.3 (AUTHOR), Trojan, J.7 (AUTHOR), Vogl, T.J.J.8 (AUTHOR), Zeuzem, S.3 (AUTHOR), Finkelmeier, F.7 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS669-S669. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 179692435 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 979P Initial results from the phase II randomized trial comparing TACE with irinotecan and mitomycin C to doxorubicin in intermediate stage HCC (IRITACE trial). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Waidmann%2C+O%2E%22">Waidmann, O.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gruber-Rouh%2C+T%2E%22">Gruber-Rouh, T.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Koch%2C+C%2E%22">Koch, C.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Götze%2C+T%2EO%2E%22">Götze, T.O.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schultheiss%2C+M%2E%22">Schultheiss, M.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Herrmann%2C+E%2E%22">Herrmann, E.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Steup%2C+C%2E%22">Steup, C.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Trojan%2C+J%2E%22">Trojan, J.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vogl%2C+T%2EJ%2EJ%2E%22">Vogl, T.J.J.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zeuzem%2C+S%2E%22">Zeuzem, S.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Finkelmeier%2C+F%2E%22">Finkelmeier, F.</searchLink><relatesTo>7</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2024 Supplement 2, Vol. 35, pS669-S669. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=179692435 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2024.08.1039 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S669 Titles: – TitleFull: 979P Initial results from the phase II randomized trial comparing TACE with irinotecan and mitomycin C to doxorubicin in intermediate stage HCC (IRITACE trial). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Waidmann, O. – PersonEntity: Name: NameFull: Gruber-Rouh, T. – PersonEntity: Name: NameFull: Koch, C. – PersonEntity: Name: NameFull: Götze, T.O. – PersonEntity: Name: NameFull: Schultheiss, M. – PersonEntity: Name: NameFull: Herrmann, E. – PersonEntity: Name: NameFull: Steup, C. – PersonEntity: Name: NameFull: Trojan, J. – PersonEntity: Name: NameFull: Vogl, T.J.J. – PersonEntity: Name: NameFull: Zeuzem, S. – PersonEntity: Name: NameFull: Finkelmeier, F. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2024 Supplement 2 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 35 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
